Merck Has Agreed To Acquire CN201, An Investigational Clinical-stage Bispecific Antibody For B-cell Associated Diseases, From A Privately Held Curon Biopharmaceutical For An Upfront Payment Of $700M In Cash And Up To $600M In Milestone Payments
Merck Has Agreed To Acquire CN201, An Investigational Clinical-stage Bispecific Antibody For B-cell Associated Diseases, From A Privately Held Curon Biopharmaceutical For An Upfront Payment Of $700M In Cash And Up To $600M In Milestone Payments
CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and relapsed or refractory B-cell acute lymphocytic leukemia (ALL), respectively. Preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, with the potential to induce significant and sustained reductions in B-cell populations. Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases.
CN201正在进行I期和Ib/II期临床试验，用于治疗复发或难治性非何杰金淋巴瘤（NHL）和难治性b细胞急性淋巴细胞白血病（ALL）。初步数据表明，CN201在复发或难治性b细胞造血系统恶性肿瘤患者中有活性，并且耐受性良好，具有潜力诱导显著和持续的b细胞群体减少。默沙东计划将CN201作为b细胞恶性肿瘤的治疗方案，并研究其提供自身免疫性疾病治疗的新型可扩展选择的潜力。
